Important Safety Information  |  Full Prescribing Information
  • Text Size  A | A | A
  • Reimbursement & Access Support

    Spectrum is committed to helping you and your patients access FUSILEV

    STAR® Program Logo
    1-888-53-STAR-7 or 1-888-537-8277

    The Spectrum Therapy Access Resources (STAR)® Program provides reimbursement specialists to assist with:

    • Benefit verification including payer-specific coverage, billing, and coding information
    • Prior authorizations when required
    • Appeals process for denied benefits up to the highest level of appeal

    For patients who need assistance accessing FUSILEV, reimbursement specialists with the STAR Program
    can help:

    • Commercially-insured patients with co-pay or co-insurance drug costs once an application has been approved and an explanation of benefits (EOB) has been provided
    • Uninsured patients by providing FUSILEV free-of-charge for those who meet program eligibility requirements
    • Underinsured patients by identifying alternate coverage and resources, such as independent co-pay foundations

    †The STAR program does not provide assistance with deductibles. Spectrum Pharmaceuticals does not guarantee coverage and/or reimbursement. Coverage, coding, and reimbursement policies vary significantly by payer, patient, and setting of care. Actual coverage and reimbursement decisions are made by individual payers following the receipt of claims. HCPs should always verify coverage, coding, and reimbursement guidelines on a payer and patient-specific basis.
    ‡Government insured patients (Medicare, Medicaid, etc) are not eligible for this program.

    Download the STAR Program Application

    Indications and Usage

    FUSILEV is a folate analog indicated for:

    • Rescue after high-dose methotrexate therapy in osteosarcoma.
    • Diminishing the toxicity and counteracting the effects of impaired methotrexate elimination and of inadvertent overdosage of folic acid antagonists.
    • Use in combination chemotherapy with 5-fluorouracil in the palliative treatment of patients with advanced metastatic colorectal cancer.

    Limitations of Use

    • FUSILEV is not approved for pernicious anemia and megaloblastic anemias. Improper use may cause a hematologic remission while neurologic manifestations continue to progress.

    Important Safety Information


    • FUSILEV is contraindicated for patients who have had previous allergic reactions attributed to folic acid or folinic acid.

    Warnings and Precautions

    • Due to Ca++ content, no more than 16 mL (160 mg) of levoleucovorin solution should be injected intravenously per minute.
    • FUSILEV enhances the toxicity of fluorouracil.
    • Concomitant use of d,l-leucovorin with trimethoprim-sulfamethoxazole for Pneumocystis carinii pneumonia in HIV patients was associated with increased rates of treatment failure in a placebo-controlled study.

    Adverse Reactions

    • Allergic reactions were reported in patients receiving FUSILEV.
    • The most common adverse reactions (>50%) in patients with advanced colorectal cancer receiving FUSILEV in combination with 5-FU were diarrhea, nausea and stomatitis.
    • Vomiting (38%), stomatitis (38%) and nausea (19%) were reported in patients receiving FUSILEV as rescue after high-dose methotrexate therapy.

    Drug Interactions

    • FUSILEV may counteract the antiepileptic effect of phenobarbital, phenytoin and primidone, and increase the frequency of seizures in susceptible patients.

    Please click here to see full Prescribing Information for FUSILEV.